Literature DB >> 16909113

Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.

R G Weber1, A Hoischen, M Ehrler, P Zipper, K Kaulich, B Blaschke, A J Becker, S Weber-Mangal, A Jauch, B Radlwimmer, J Schramm, O D Wiestler, P Lichter, G Reifenberger.   

Abstract

The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood. We characterized 50 PXAs by comparative genomic hybridization (CGH) and found the most common imbalance to be loss on chromosome 9 in 50% of tumors. Other recurrent losses affected chromosomes 17 (10%), 8, 18, 22 (4% each). Recurrent gains were identified on chromosomes X (16%), 7, 9q, 20 (8% each), 4, 5, 19 (4% each). Two tumors demonstrated amplifications mapping to 2p23-p25, 4p15, 12q13, 12q21, 21q21 and 21q22. Analysis of 10 PXAs with available high molecular weight DNA by high-resolution array-based CGH indicated homozygous 9p21.3 deletions involving the CDKN2A/p14(ARF)/CDKN2B loci in six tumors (60%). Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions. Mutational analysis of candidate genes on 9q, PTCH and TSC1, revealed no mutations in PXAs with 9q loss and no evidence of TSC1 promoter methylation. However, PXAs consistently showed low TSC1 transcript levels. Taken together, our study identifies loss of chromosome 9 as the most common chromosomal imbalance in PXAs and suggests important roles for homozygous CDKN2A/p14(ARF)/CDKN2B deletion as well as low TSC1 mRNA expression in these tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909113     DOI: 10.1038/sj.onc.1209851

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.

Authors:  Jeffrey C Murray; David J Donahue; Saleem I Malik; Yvette B Dzurik; Emily Z Braly; Margaret J Dougherty; Katherine W Eaton; Jaclyn A Biegel
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

2.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.

Authors:  Rachael A Vaubel; Alissa A Caron; Seiji Yamada; Paul A Decker; Jeanette E Eckel Passow; Fausto J Rodriguez; Amulya A Nageswara Rao; Daniel Lachance; Ian Parney; Robert Jenkins; Caterina Giannini
Journal:  Brain Pathol       Date:  2017-04-02       Impact factor: 6.508

4.  Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Authors:  Cristiane M Ida; Fausto J Rodriguez; Peter C Burger; Alissa A Caron; Sarah M Jenkins; Grant M Spears; Dawn L Aranguren; Daniel H Lachance; Caterina Giannini
Journal:  Brain Pathol       Date:  2014-12-05       Impact factor: 6.508

Review 5.  Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Authors:  Elisabet Pujadas; Liam Chen; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2019-03-11       Impact factor: 3.298

6.  Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.

Authors:  Aisulu Usubalieva; Christopher R Pierson; Christina A Kavran; Kristin Huntoon; Oleksandr N Kryvenko; Theodore G Mayer; Weiqiang Zhao; Jack Rock; Mario Ammirati; Vinay K Puduvalli; Norman L Lehman
Journal:  J Neuropathol Exp Neurol       Date:  2015-10       Impact factor: 3.685

7.  Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

Authors:  Jae Kyung Myung; Hwajin Cho; Chul-Kee Park; Seung-Ki Kim; Se-Hoon Lee; Sung-Hye Park
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 8.  Molecular markers in pediatric neuro-oncology.

Authors:  Koichi Ichimura; Ryo Nishikawa; Masao Matsutani
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 9.  Aggressive behavior and anaplasia in pleomorphic xanthoastrocytoma: a plea for a revision of the current WHO classification.

Authors:  Nesibe Kahramancetin; Tarik Tihan
Journal:  CNS Oncol       Date:  2013-11

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.